Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960496 | 1.00 | RAB9A (0.59) | RAB9AEPHX2HSD11B1TDP1KMT2A | |
| SCHEMBL610166 | 1.00 | RAB9A (0.59) | RAB9AEPHX2HSD11B1TDP1KMT2A | |
| SCHEMBL4962248 | 0.89 | EPHX2 (0.57) | RAB9AEPHX2HSD11B1KMT2AMEN1 | |
| SCHEMBL610142 | 0.89 | EPHX2 (0.57) | RAB9AEPHX2HSD11B1KMT2AMEN1 | |
| SCHEMBL612149 | 0.87 | EPHX2 (0.66) | RAB9AEPHX2HSD11B1TDP1KMT2A | |
| SCHEMBL612150 | 0.87 | EPHX2 (0.66) | RAB9AEPHX2HSD11B1TDP1KMT2A | |
| SCHEMBL610923 | 0.84 | EPHX2 (0.68) | RAB9AEPHX2HSD11B1TDP1KMT2A | |
| SCHEMBL610924 | 0.84 | EPHX2 (0.68) | RAB9AEPHX2HSD11B1TDP1KMT2A | |
| SCHEMBL4962004 | 0.84 | EPHX2 (0.68) | RAB9AEPHX2HSD11B1TDP1KMT2A | |
| SCHEMBL611727 | 0.83 | EPHX2 (0.67) | RAB9AEPHX2HSD11B1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | claimed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | claimed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | RAB9A 2691/4885EPHX2 1175/4885HSD11B1 1/4885 |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | RAB9A 2077/4885EPHX2 1552/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.